At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Lenalidomide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Lenalidomide, and 1 other intervention for Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Novartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedMar 2014
Primary CompletionJan 2018
Study CompletionAug 2021
TodayJul 2026
First PostedMar 13, 2014
Enrollment StartJan 17, 2014
Primary CompletionJan 15, 2018
Study CompletionAug 13, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 12.3 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Lenalidomidedrug
Given PO
Sonidegibdrug
Given PO